AAPG - Ascentage Pharma Quarterly EPS earnings growth
Volatility in quarterly EPS dynamics is driven by uncertainty regarding regulatory drug approval timelines, where the current level is 0.00. The financial result is based on sales of the drug olverembatinib. Ascentage Pharma Group's status as a bold innovator in oncology strengthens its authority within the global scientific community, confirming the resilience of the chosen operational business model.
%20Earnings%20per%20share%20growth%20in%20annualized%20terms%20for%20the%20last%20twelve%20months&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_AAPG_-_Ascentage-Pharma-Group_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "Ascentage Pharma Group (AAPG): Quarterly EPS earnings growth from 01/25/2025 to 11/15/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns and data insights for company Ascentage Pharma Group (AAPG)
- market value and analyst target forecast:
- market capitalization statistics:
- balance sheet net asset value indicators:
- company liabilities and liquidity data:
Total Debt to Capital Ascentage Pharma Group|AAPG - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Ascentage Pharma Corp|AAPG - Company Cumulative Debt|Debt to Book Capitalization Ratio Ascentage Pharma Group International|AAPG - Company Long-Term Indebtedness|Company Current Liabilities Ascentage Pharma|Quick Ratio ascentage.com
- earnings and valuation multiples indicators:
AAPG - Net Profit|Projected Future Earnings Ascentage Pharma Group|AAPG - Market Cap to Net Income Ratio|Forward P/E Multiple Ascentage Pharma Group International|AAPG - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Ascentage Pharma Group|AAPG - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Ascentage Pharma|AAPG - Earnings per one share for the last 12 months|Quarterly EPS earnings growth ascentage.com|AAPG - Earnings per share increase in current year|Earnings growth forecast for next year Ascentage Pharma Group
- revenue and sales details:
Comprehensive company analysis:Ascentage Pharma Group
Fundamental screening begins with an analysis of earnings per share dynamics. This indicator measures the percentage change in EPS between the current and previous quarters, reflecting the rate of capital scaling. By analyzing the current quarterly EPS growth rate, an investor identifies inflection points in market value. For Ascentage Pharma Group (AAPG), such fluctuations signal a reassessment of oncology drug development prospects. The outcome here depends on the success of clinical trials rather than macroeconomics.
Key competitors
ONC: Quarterly EPS earnings growth|Halozyme Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (Revolution Medicines Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months CG Oncology, Inc. CGON|Year-over-year net earnings per share growth for the last 12 months URGN (urogen.com)|Year-over-year earnings per share growth for the last twelve months BCAX (Bicara Therapeutics)|Quarterly EPS earnings growth PSNL (personalis.com)|Year-over-year earnings per one share growth for the last 12 months ERAS|DCTH - Year-over-year earnings per share growth for the last twelve months|Y-mAbs Therapeutics (YMAB) - Year-over-year net earnings per share growth for the last 12 months|AURA: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months CADL|Year-over-year earnings per share growth for the last twelve months Accuray Inc.|SELLAS Life Sciences Group (SLS) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ACTU (Actuate Therapeutics, Inc)|Year-over-year net earnings per share change for the last twelve months Citius Oncology|TuHURA Biosciences, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Protara TARA|fatetherapeutics.com - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aadi Bioscience|TCRX: Quarterly EPS earnings growth|CSBR - Year-over-year net earnings per share change for the last twelve months|XBIT (XBiotech) - Quarterly EPS earnings growth|CVM: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth OSTX|RADX (Radiopharm Theranostics Limited) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ARTV (Artiva Biotherapeutics, Inc.)|Year-over-year earnings per one share growth for the last 12 months ANL|VERU: Year-over-year net earnings per share growth for the last 12 months|TPST - Quarterly EPS earnings growth|XLO (xiliotx.com) - Year-over-year net earnings per share growth for the last 12 months|Renovaro Biosciences - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months MURA|Year-over-year earnings per share growth for the last twelve months KAPA|Year-over-year net earnings per share growth for the last 12 months OKUR (OnKure Therapeutics Inc)|Quarterly EPS earnings growth CytoMed (GDTC)|Year-over-year earnings per share growth for the last twelve months curis.com CRIS|APLM (Apollomics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|Tharimmune Corporation - Quarterly EPS earnings growth|ADVB (advanbiomed.com) - Year-over-year earnings per share growth for the last 12 months|Genprex, Inc (GNPX) - Year-over-year earnings per share growth for the last twelve months|CLDI: Year-over-year earnings per share growth rate for the last twelve months|SBFM (Sunshine Biopharma, Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months XBIO (Xenetic Biosciences)|Quarterly EPS earnings growth SLRX|Purple Biotech - Year-over-year earnings per share growth for the last 12 months|American Oncology Network - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months BGNE|CKPT - Year-over-year earnings per share growth for the last twelve months|Elevation Oncology (ELEV) - Year-over-year net earnings per share growth for the last 12 months|ICAD: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Ikena Oncology Inc.|NTBL (Notable Labs Ltd) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Viracta Therapeutics (VIRX)|Year-over-year earnings per share growth for the last twelve months MorphoSys Corporation (MOR)|NAYA (NAYA Biosciences) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AAPGV (Ascentage)
